miRNA and antisense oligonucleotide-based α-synuclein targeting as disease-modifying therapeutics in Parkinson's disease. Alzforum, 16 Dec 2022 Suvarna V, Deshmukh K, Murahari M. Front Pharmacol. 2022;13:1034072. Epub 2022 Nov 15 PubMed.